Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 8Plasma cell 2Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Multiple Myeloma 2Carcinoma, Non-Small-Cell Lung 1

Interventions

Dexamethasone 293Lenalidomide 162Bortezomib 160Cyclophosphamide 121Calcium Dobesilate 118Melphalan 116fludarabine phosphate 75carfilzomib 62pomalidomide 57Whole-Body Irradiation 57Mycophenolic Acid 56Granulocyte Colony-Stimulating Factor 55Peripheral Blood Stem Cell Transplantation 54Filgrastim 54fludarabine 50daratumumab 50Tacrolimus 45Busulfan 45ixazomib 42Thalidomide 37Cyclosporine 32Stem Cell Transplantation 29dexamethasone acetate 28Antilymphocyte Serum 26dexamethasone 21-phosphate 23plerixafor 21elotuzumab 20auricularum 20belantamab mafodotin 19Prednisone 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × L-BLP25 × Plasma cell × Clear all
NCT01423760 2016-10-06

Common Safety Follow-up Trial of Tecemotide (L-BLP25)

Merck KGaA, Darmstadt, Germany

Phase NA Terminated
27 enrolled 7 charts
Plasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Multiple Myeloma

NCT01094548 2016-02-22

Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy

Merck KGaA, Darmstadt, Germany

Phase 2 Completed
34 enrolled 12 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡